A sensitive enzymatic procedure has been developed for the determination of guanosine 3': 5'-cyclic monophosphate (cyclic GMP). It is based on the conversion of cyclic GMP to GMP by cyclic nucleotide phosphodiesterase and on the transfer of 32p from [7--32P] Cyclic nucleotide concentrations were studied in the ductus deferens of the rat; two agents were used, carbachol and norepinephrine, which cause contraction. Incubation with 0.1 mM carbachol caused a 3-fold increase in cyclic GMP content, which was maximal about 2 min after carbachol addition. Cyclic AMP concentrations were not significantly changed. Addition of 0.01 mM norepinephrine increased cyclic GMP content by about 25% within 1 min and by 40% within 3 min; cyclic AMP concentrations were only slightly increased. A 3-min incubation with the phosphodiesterase inhibitor 1-methyl-3-isobutylhanthine (0.1 mM) doubled the cyclic GMP content and increased cyclic AMP concentration by 50%.
While adenosine 3': 5'-cyclic monophosphate (cyclic AMP) has been established as an intracellular mediator in the action of various hormones (1) , the role of guanosine 3': 5'-cyclic monophosphate (cyclic GMP) is still unclear. This cyclic nucleotide, which was first discovered in rat urine (2) , has been found in all mammalian tissues examined but in concentration much lower than those of cyclic AMP (3) (4) (5) .
The present paper describes a new enzymatic assay for small amounts of cyclic GMP. The assay is based on the following enzymatic steps: phosphodiesterase Cyclic GMP - .GMP [1] [,y 12P
GMP kinase 32 GMP++ [-P]ATP k-----[ 32P]GDP+ADP [2] [ y 32
p myosin + 32p
[y~]ATP -* ADP +P1 [3] After conversion of cyclic GMP to [32P]GDP and degradation of the the remaining [32P]ATP to ADP and 32Pi, the Pi is precipitated, and the amount of [32P]GDP in the supernatant fluid is determined. This assay has been applied to studies on the control of cyclic GMP content in the ductus deferens of the rat. Cyclic GMP concentrations were increased after incubation with carbachol or norepinephrine, agents that cause a contraction of this smooth muscular tissue.
MATERIALS AND METHODS
Enzymes. Cyclic nucleotide phosphodiesterase was purified from bovine hearts (6) . The specific activity was 0.4-0.5 ,mol min-' mg-' of protein if determined according to Beavo et al. (7) with 1 MM cyclic GMP as substrate. Protein was determined according to Lowry et al. (8) . ATP:GMP phosphotransferase (GMP kinase, EC 2.7.4.8) was a commercial preparation from pig brain (specific activity 10 U/ mg) by Boehringer Mannheim Corp. or was prepared from calf thymus (9) with a similar specific activity. Before use, the pig brain enzyme was dialyzed over night against 500-1000 volumes of 10 mM N-tris(hydroxymethyl)-methyl-2-amonimethane sulfonate (TES) buffer (pH 7.4). Myosin was prepared from rabbit skeletal muscle (10) with two additional precipitations. The enzyme was stored at -20°in a solution containing 0.25 M KCl and 50% (v/v) glycerol (11) . When assayed as described by Perry (10) , the preparations hydrolyzed at least 2 the Pi was incorporated into ATP. This was checked by addition of a few milligrams of Norit A to a small aliquot of the incubation medium that had been transferred into 1 ml of 0.5 M KH2PO4 in 0.1 N HCl and counting of aliquots before and after the charcoal addition (13). The incubation was stopped by application of a part Mul) of the incubation mixture in a 4-cm band to a thin-layer chromatography plate coated with polyethyleneimine cellulose (Serva, Heidelberg, Germany) (14) ; the rest was frozen, and aliquots were chromatographed as needed. The plates were developed at 2-4°1 (15) .
The tissue was then transferred for the time indicated to flasks containing fresh medium with additions as indicated.
Extraction and Purification of Cyclic Nucleotides. The tissue was fixed by freezing inliquidnitrogen-cooled aluminum clamps. The frozen tissue was broken into small pieces in a N2-cooled mortar and then homogenized in a conical ground-glass homogenizer (Duall size 23, Kontes Glass Comp.) in 2 ml of 50% ethanol cooled to -20°to which were added 200 Ml of a solution containing 1 M zinc acetate and tracer amounts of tritiated cyclic AMP and cyclic GMP (about 15 nCi of each). The homogenate was transferred to a centrifuge tube, and the homogenizer was rinsed with 2 ml of 50% ethanol which are then added to the homogenate. After centrifugation for 10 min at 50,000 X g, 100 /ud of 2 M Na2CO3 were added to the supernate. While most of the 5'-nucleotides are coprecipitated with the ZnCO3 formed (16), little if any cyclic AMP and only about 15% of the cyclic GMP are precipitated. After centrifugation for 10 min at 50,000 X g, the supernatant (followed by 6 ml of H20) was filtered through a 0.7 X 1.5-cm column of neutral Dowex-50 (in the NH4+ form) to remove all Zn++.
The cyclic nucleotides were further purified on a 0.7 X 4-cm column of QAE-Sephadex A-25 in the formate form. The application of the sample was followed by 10 ml of H20 and then by 6 ml of 0.1 M ammonium formate adjusted to pH 9.0 with NH40H. The eluting fluid was then changed to 0.1 M ammonium formate adjusted to pH 6.0 with formic acid, and the first 5.5 ml, containing cyclic AMP, were collected. The following 3 ml were discarded, and the next 5.5 ml of the eluate, containing cyclic GMP, were collected. The cyclic nucleotide fractions were lyophilized, and the dried samples were taken up in 0.5-1 ml of H20 or dilute buffer. The overall recoveries, which are 60-70% for cyclic AMP and 40-50% for cyclic GMP, were determined by counting aliquots of the samples in "tT-21" scintillation fluid (17) in a liquid scintillation spectrometer. Cyclic AMP was determined by a modified procedure (4) using a phosphate-generating, enzymatically cycling system (18) .
General Procedure for Cyclic GMP Determination. Cyclic GMPwashydrolyzed byO. The incubation with GMP kinase from calf thymus and phosphodiesterase was performed with 2 pmol of ATP (8600 cpm). GDP and GTP were purified by thin-layer chromatography before use. The values are the counts remaining in the supernatant fluid after precipitation of the 32P. released during the (Fig. 2) .
Assay Specificity. The specificity of the assay is assured by chromatographic purification of samples to be assayed and by the high substrate specificities of the cyclic nucleotide phosphodiesterase and of the ATP: GMP phosphotransferase. The possibilities for interference by other nucleotides was tested as follows. Several nucleoside monophosphates were included in the assay system in high amounts (100 pmol per tube), with 2 32p incorporation was observed although the compound had been purified by thin-layer chromatography on polyethyleneimine cellulose (14) . None of the compounds yielding phosphorylated, myosin-stable products required the presence of phosphodiesterase for 32p incorporation. The small effects observed with all the above compounds are probably due to small side activities of the GMP kinase for other nucleoside monophosphates or to contaminations with other nucleotides (e.g., of the GTP and perhaps of the CoA).
Two other compounds directly affected the GMP kinase reaction. Addition of GDP (20 pmol per tube, also purified by thin-layer chromatography) resulted in the transfer from due to an exchange reaction of the terminal phosphate groups between ATP and GDP catalyzed by the GMP kinase. ADP (20 pmol per tube), however, reduced the counting rate observed in the absence of cyclic GMP as well as a complete prevention of the conversion of cyclic GMP to [32P]GDP. This apparent inhibition of GMP phosphorylation by ADP could also be observed with much lower amounts of ADP.
Cyclic Nucleotide Concentrations in Rat Ductus Deferens. Cyclic nucleotide concentrations were measured in segments of rat ductus deferentes. Basal cyclic GMP concentrations were about 55 pmol/g of wet weight; those of cyclic AMP were 900-1000 pmol/g. When the tissue was incubated with 0.1 mM carbachol-a concentration that is almost maximally effective with regard to stimulating contraction-cyclic GMP was rapidly increased. The content of this cyclic nucleotide was doubled 30 sec after addition of carbachol and reached a maximum within about 2 min with a subsequent slow decline ( Table 2 ). Cyclic AMP concentrations were not significantly affected. Choline (0.1 mM), which does not induce a contraction of the ductus deferens, did not change the cyclic nucleotide content measured 2 min after its addition.
The effect of norepinephrine on cyclic nucleotide content was also studied in this tissue (Table 3) . Norepinephrine was added in a 0.01 mM concentration, which is approximately half maximally effective with respect to contraction. Cyclic GMP concentrations were increased by 25% after 1 min and by 40% after 3 and 10 min. Consistent small elevations of cyclic AMP concentrations were observed with this concentration of norepinephrine.
Incubation of the tissue for 3 min with the phosphodiesterase inhibitor SC-2964 (0.1 mM) more than doubled cyclic GMP content, but increased cyclic AMP concentrations by only 50% (see Table 3 ).
DISCUSSION
Within the last few years several methods have been described for determination of cyclic GMP concentration. In their principles, these assays are very similar to methods that are in use for determination of cyclic AMP concentration. The assays for cyclic GMP are based on enzymatically cycling systems (3, 4, 18) , activation of cyclic GMP-Stimulated protein kinases (21) , or competition for binding by a protein kinase (22) or by a specific antibody (23) . The principle of the assay described in the present paper is similar to that of a method that has been described by Turtle and Kipnis (24) for the determination of cyclic AMP, but that has not found wide application.
Only two of the assays mentioned above, the cycling system described by Goldberg et al. (3) (25) , heart and brain slices (21) , intestinal smooth muscle (26, 27) , and slices of thyroid (28) and submaxillary glands (27) , while cyclic AMP concentrations were not affected or were only slightly decreased. In the present work, contraction-producing cholinergic stimulation of the ductus deferens also led to an increase of cyclic GMP content.
Low concentrations of norepinephrine also caused a significant increase in cyclic GMP content of rat ductus deferens while cyclic AMP concentrations were only slightly increased. In some experiments atropine has caused a partial reduction of the effect of norepinephrine on cyclic GMP content while having no effect on the contraction produced by this hormone. Thus, it is not clear yet if the effect of norepinephrine on cyclic GMP content is a direct one or if it is mediated by the release of endogenous acetylcholine from nerve endings in the tissue. As conditions involving increased concentrations of intracellular free calcium are connected with increased cyclic GMP content (27) , it is conceivable that a-adrenergic stimulation of the ductus deferens does cause a Ca++-mediated increase in cyclic GMP. Whether or not increased cyclic GMP content-in combination with increased intracellular Ca++ concentration-is involved in the contractile response of the tissue to hormonal stimulation is unknown.
Incubation of the ductus deferens for 3 min with the phosphodiesterase inhibitor SC-2964 caused increases in the concentrations of both cyclic nucleotides. The effect on cyclic GMP, however, was much more pronounced than that on cyclic AMP. Unlike acetylcholine and norepinephrine, SC-2964 causes relaxation of the contracted ductus deferens. The observation that agents causing either contraction or relaxation of the ductus deferens can raise cyclic GMP concentration suggests that if this cyclic nucleotide plays a role in smooth muscle function, it does so by interacting with other regulatory factors, e.g., with cyclic AMP and Ca++.
